



MEDIGARD LIMITED

Office 14A, Tedder Terraces, 26-30 Tedder Avenue, Main Beach QLD 4217

Telephone +61 7 5528 0370; Fax +61 7 5528 0275

E-mail office@medigard.com.au www.medigard.com.au

ABN 49 090 003 044

10 August, 2010

Manager of Company Announcements
Australian Stock Exchange Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

No of pages: 3 inclusive

Despatch of Prospectus

Medigard Limited advises that the Prospectus for its Renounceable Rights Issue has been despatched today. Shareholders should receive the Prospectus in the mail within the next few days.

Attached please find a Letter to Shareholders which was enclosed with the Prospectus.

Peter Emery
Chief Executive Officer

For further information contact:
Peter Emery, Telephone (07) 5528 0370



MEDIGARD LIMITED

ABN 49 090 003 044

Office 14A, Tedder Terraces, 26-30 Tedder Avenue, Main Beach QLD 4217

Telephone +61 7 5528 0370; Fax +61 7 5528 0275

E-mail office@medigard.com.au www.medigard.com.au

10 August 2010

Dear Shareholder,

Shareholder Presentations

You will be aware that Medigard Limited is currently raising capital through the Rights Issue Prospectus to its shareholders. Only registered shareholders of Medigard can participate in this issue. Under this Prospectus, Shares will be issued at 6.5c with a free attached option. Funds raised from this Issue will be used for the production tooling and assembly equipment for Medigard's Blood Collection Device and for its 3mL Safety Auto- Retractable Syringe, and for the development of Medigard's suite of other products. In order to inform our shareholders of Medigard's development and the Rights Issue, the Company will be holding two information presentations in Brisbane and Cairns. The details of these presentations are:

Brisbane	Cairns
Brisbane Polo Club Cnr Eagle and Felix Streets, Brisbane 5:30pm for 6.00pm Tuesday 17 August, 2010 RSVP 07 5528 0370	Sebel Hotel 17 Abbott Street, Cairns 5.30pm for 6.00pm Friday 13 August, 2010 RSVP 07 5528 0370

We hope that you will be able to attend this function. We encourage you to invite your friends and interested parties to join us at the presentation.

Rights Issue and Trading

Each and every shareholder of Medigard has received "Rights" to purchase shares in Medigard at 6.5c. Shareholders should be aware that these "Rights" have value, and are tradable on the ASX under the code MGZR. Shareholders may sell their "Rights" if they do not wish to take up all of their Entitlement. Conversely, if shareholders wish to purchase "Rights", they are also able to do this on the ASX. Trading in the "Rights" began on 30 July, and it ceases on 18 August. Should you have any questions about the "Rights" trading, you are advised to seek professional advice or to phone Peter Emery (CEO) or Peter Clark (Executive Director) at Medigard.

Radio Interview

Recently, our CEO, Peter Emery, recorded a radio interview on Board Room Radio. Board Room Radio is widely distributed to:

- Financial information portals
- Broker websites
- Share-trading chat rooms
- Industry bodies
- Other relevant entities

We encourage you to listen to this interview. The link to this interview can be found at: brr.com.au/event/preview/6f75p42erv/67520

Contact Details for Registries

It is important that your registration and contact details are recorded correctly on the share register. If you would like to update your details, Medigard strongly urges you to please visit InvestorServe at investorserve.com.au or contact the Company's share register office:

Phone (02) 9290 9600


Fax (02) 9279 0664

Email registries@registries.com.au

InvestorServe is a user-friendly and secure website operated by our share registry, Registries Limited. This website allows you to view and update details of your shareholding in the Company such as banking instructions and transaction. All holders were recently sent a letter which contained an InvestorServe Password and instructions of how to log on to InvestorServe.

We value enormously the support and patience of our shareholders and look forward to that continuing as we bring our products to market.

Yours Sincerely



Peter Emery
CEO